Napo Pharmaceuticals INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSan Francisco, CA
US patents17
SAM.gov UEIGNMTLLK5JQE5
CAGE code5DTK4
Incorporated inDE
Patents
17 US patents granted 2008–2024, 3 of them in the five years to SEP 2025.
Pharmaceuticals 17
- Methods and compositions for treating congenital diarrhea disorderUS 11,857,510 · granted JAN 2, 2024
- Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndromeUS 11,779,564 · granted OCT 10, 2023
- Methods and compositions for treating chemotherapy-induced diarrheaUS 11,389,424 · granted JUL 19, 2022
- Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancerUS 9,987,250 · granted JUN 5, 2018
- Method for treatment of diarrhea-predominant irritable bowel syndromeUS 9,980,938 · granted MAY 29, 2018
Newest 5 shown · Granted to Napo Pharmaceuticals, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Napo Pharmaceuticals INC | San Francisco | CA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.